Telo Genomics Corp
TSXV:TELOView on OTCQB

  • LAST PRICE
    0.1700
  • TODAY'S CHANGE (%)
    -0.0100 (-5.5556%)
  • Bid / Lots
    0.1800/ 2
  • Ask / Lots
    0.1900/ 3
  • Open / Previous Close
    0.1700 / 0.1800
  • Day Range
    0.1700
    0.1700
  • 52 Week Range
    0.1050
    0.2950
  • Volume
    10,000

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Sep 10, 2024

      Show headlines and story abstract

    • 8:46AM ET on Tuesday Sep 10, 2024 by Newsfile
      Companies Mentioned: TDSGF

      Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it is evaluating its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma (MM) patients as a part of the TELO-DMRD clinical validation study.

    • 8:46AM ET on Tuesday Sep 10, 2024 by Dow Jones
      Companies Mentioned: TELO

      Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it is evaluating its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma (MM) patients as a part of the TELO-DMRD clinical validation study.

  • Aug 13, 2024

      Show headlines and story abstract

    • 8:46AM ET on Tuesday Aug 13, 2024 by Newsfile
      Companies Mentioned: TDSGF

      Toronto, Ontario--(Newsfile Corp. - August 13, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that the US Centres of Medicare & Medicaid Services (CMS) which regulates the medical laboratories in the USA, has awarded Telo its Clinical Laboratory Improvement Amendment ("CLIA") certificate of registration, as a certified medical clinical laboratory. Telo's registration is within the international stream of CLIA.

    • 8:46AM ET on Tuesday Aug 13, 2024 by Dow Jones
      Companies Mentioned: TELO

      Toronto, Ontario--(Newsfile Corp. - August 13, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that the US Centres of Medicare & Medicaid Services (CMS) which regulates the medical laboratories in the USA, has awarded Telo its Clinical Laboratory Improvement Amendment ("CLIA") certificate of registration, as a certified medical clinical laboratory. Telo's registration is within the international stream of CLIA.

Peers Headlines